Ticamet® 125 HFA Inhaler: Each single actuation provides 25 micrograms of Salmeterol (as Salmeterol Xinafoate EP) and 125 micrograms of Fluticasone Propionate BP (delivered from the valve).
Ticamet® 250 HFA Inhaler: Each single actuation provides 25 micrograms of Salmeterol (as Salmeterol Xinafoate EP) and 250 micrograms of Fluticasone Propionate BP (delivered from the valve).
Ticamet® HFA inhaler is indicated in the regular treatment of asthma where use of a combination product (long-acting β₂ agonist and inhaled corticosteroid) is appropriate:
Adults and adolescents 12 years and older:
Special Group: There is no need to adjust the dose in elderly patients or in those with renal impairment or hepatic impairment.
Ticamet® HFA inhaler should not be used to treat acute asthma symptoms for which a fast and short acting bronchodilator is required. Treatment with Ticamet® should not be stopped abruptly. As with all inhaled medication containing corticosteroids, Ticamet® should be administered with caution in patients with pulmonary tuberculosis. Rarely, Ticamet® may cause cardiac arrhythmias e.g. supraventricular tachycardia, extrasystoles and atrial fibrillation and a mild transient reduction in serum potassium at high therapeutic doses.
Children and adolescents <16years taking high doses of fluticasone propionate (typically 1000 microgram/day) may be at particular risk of systemic effects.
Pregnancy & Lactation:
Administration of Ticamet® to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
Keep out of the reach of children. Store below 30°C protected from direct sunlight and heat. Keep away from contact of eyes. The container should not be punctured, broken or burnt even when apparently empty.